Rating Change
Wells Fargo reiterated its Overweight rating on Axsome Therapeutics, Inc. (NASDAQ:AXSM) on August 11, 2026.
reiterateNASDAQ:AXSM
Wells Fargo Reiterates Overweight Rating on Axsome Therapeutics, Inc. (AXSM)
Wells Fargo reiterated its Overweight rating on Axsome Therapeutics, Inc. (NASDAQ:AXSM) on August 11, 2026.
At publication ·
What changed
Axsome Therapeutics, Inc. (NASDAQ:AXSM) · reiterate
- Firm
- Wells Fargo
- Rating
- Overweight to Overweight
- Price at event
- $215.77
- Market capitalization
- $7.5B
At a glance
Key takeaways
- Wells Fargo reiterated an Overweight rating on Axsome Therapeutics (AXSM) on August 11, 2026, with the stock trading at $215.77 and a market capitalization of $7.5 billion.
- Among the 10 most recent analyst ratings, 9 are Buy ratings, 1 is Hold, and 0 are Sell, indicating predominantly positive sentiment from the analyst community.
- Axsome stock has gained 110.8% over the past 52 weeks, reflecting significant appreciation in the healthcare sector.
- Analyst ratings and price targets are one input among many for investment decisions, and historical studies show that consensus recommendations alone have mixed predictive power.
Market Context
Axsome Therapeutics, Inc. operates in the Healthcare sector. The stock currently trades at $215.77 with a market capitalization of $7.5B. The stock has gained 110.8% over the past 52 weeks.
Analyst coverage from Wells Fargo provides professional research and price targets that many institutional investors reference when making allocation decisions. The consensus of analyst opinions — along with the range of price targets — helps frame market expectations for Axsome Therapeutics, Inc.
Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.
Recent Analyst Activity for Axsome Therapeutics, Inc.
Among the 10 most recent ratings: 9 Buy, 1 Hold, 0 Sell.
| Date | Firm | Rating | Price Target |
|---|---|---|---|
| Aug 11, 2026 | RBC Capital | Outperform | N/A |
| Aug 11, 2026 | Morgan Stanley | Equal-Weight | N/A |
| Aug 11, 2026 | Guggenheim | Buy | N/A |
| Aug 11, 2026 | Wells Fargo | Overweight | N/A |
| Aug 11, 2026 | Needham | Buy | N/A |
Related Tools: Analyst Ratings Dashboard | View AXSM Stock Page
Frequently Asked Questions
What does the Overweight rating mean for AXSM?
A rating of Overweight from Wells Fargo reflects the analyst's outlook on Axsome Therapeutics, Inc. (NASDAQ:AXSM). Analyst ratings are one factor investors consider alongside earnings, valuation, and sector trends.
Where can I find more analyst ratings?
Browse recent upgrades and downgrades on our Analyst Ratings Dashboard or the AXSM forecast page.
Loading related coverage…
